Key result
Six weeks of IV vancomycin successfully treats a rare case of primary MRSA pericarditis.
Why the study?
Primary methicillin-resistant Staphylococcus aureus pericarditis is very rare in Korea and lacks detailed case descriptions.
Case Report (n=1)
This case demonstrates the successful treatment of a rare primary MRSA purulent pericarditis in a hemodialysis patient using 6 weeks of intravenous vancomycin.
Supports vancomycin in rare MRSA pericarditis; leaves open optimal regimens pending controlled data.
We report a case of a 41-year-old man undergoing hemodialysis who presented with a sudden fever and dyspnea.He developed a severe pericardial effusion due to methicillin-resistant Staphylococcus aureus, which was identified in both blood and pericardial fluid cultures.He was successfully treated with intravenous vancomycin for 6 weeks.Although such cases are very rare in Korea, the current case describes a primary purulent pericarditis without any other potential infectious foci.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2014) conducted a case report in Primary Methicillin-Resistant Staphylococcus aureus Pericarditis (n=1). Intravenous vancomycin was evaluated on Clinical recovery. Intravenous vancomycin for 6 weeks successfully treated a rare case of primary methicillin-resistant Staphylococcus aureus pericarditis in a 41-year-old man undergoing hemodialysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: